BioInvent‘s main focus is to identify and develop novel, first-in-class immuno-modulatory antibodies for cancer treatment. In other words, drugs with completely new and unique mechanisms of action with the ability to strengthen, stimulate or activate the body’s immune system so that cancer diseases can be combated.
A FULLY INTEGRATED COMPANY
One of the strengths of BioInvent is how the company has integrated research and discovery (targets and antibodies), manufacturing and clinical development under one roof. This set-up gives the company a distinct competitive advantage.
Another key feature of the company is its unique technology platform, which had generated a risk diversified first-in-class candidate portfolio, which is an excellent starting point for further successful development.
And thirdly, BioInvent is a leading international player when it comes to antibody biology and production. Put together, these three characteristics allows BioInvent to quickly identify and develop new drug candidates and contribute to the global immuno-oncology promise.
